Ibuprofen Ester Emulsion to Reduce Vascular Irritation

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Ibuprofen injections face issues such as vascular irritation, precipitation, limited administration methods, and compatibility with opioids due to its chiral carbon structure and racemic composition, leading to safety concerns and reduced efficacy.

Innovation Solution

Derivatization of the carboxyl group of racemic ibuprofen to form a dextrorotatory enantiomer N9(S) and preparation into an emulsion formulation, enhancing stability and safety while maintaining pharmacological activity.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Object-affected harmful factors

If ibuprofen is diluted to 4 mg/mL or lower to reduce vascular irritation, then vascular irritation is reduced, but patient compliance deteriorates and phlebitis still occurs

Engineering Contradiction:

Improvevascular irritationVSAvoidpatient compliance

Core Design Contradiction:

Object-affected harmful factorsVSEase of operation

Solution Approach 1:

The patent changes the chemical structure parameter of ibuprofen by introducing an ester group at the alpha position, creating a prodrug that modifies the drug's properties. This structural modification reduces vascular irritation while maintaining therapeutic efficacy, allowing for better patient compliance without requiring extreme dilution

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

The ester prodrug acts as an intermediary form that is less irritating to blood vessels upon administration. It serves as a mediator between the active ibuprofen and the vascular system, reducing direct irritation while the ester group is metabolized in the body

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If ibuprofen injection uses arginine as a solubilizer, then solubility is improved, but precipitation occurs upon dilution compromising safety

Engineering Contradiction:

ImprovesolubilityVSAvoidprecipitation

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent modifies the chemical structure by adding an ester group, which changes the solubility characteristics of the molecule. This structural parameter change eliminates the need for arginine solubilizer and prevents precipitation upon dilution, improving both reliability and safety

Inventive Principle:

Principle #35Parameter changes

3Object-affected harmful factors

If ibuprofen injection requires infusion over 30 minutes, then vascular irritation is reduced, but clinical application flexibility deteriorates

Engineering Contradiction:

Improvevascular irritationVSAvoidadministration flexibility

Core Design Contradiction:

Object-affected harmful factorsVSAdaptability or versatility

Solution Approach 1:

The ester prodrug modification changes the pharmacokinetic parameters of the drug, improving its tolerability and allowing for flexible administration routes including intravenous push injection and intramuscular injection, thereby restoring clinical flexibility while maintaining safety

Inventive Principle:

Principle #35Parameter changes

4Stability of the object's composition

If ibuprofen injection has high pH, then drug stability is improved, but compatibility with opioids deteriorates causing precipitation

Engineering Contradiction:

Improvedrug stabilityVSAvoidprecipitation with opioids

Core Design Contradiction:

Stability of the object's compositionVSObject-affected harmful factors

Solution Approach 1:

The patent changes the chemical structure to an ester prodrug, which modifies the pH characteristics and chemical properties of the injection. This structural parameter change improves compatibility with opioids like morphine hydrochloride, preventing precipitation while maintaining drug stability

Inventive Principle:

Principle #35Parameter changes

5Ease of manufacture

If racemic ibuprofen is used, then manufacturing is simplified, but efficacy deteriorates due to presence of inactive levorotatory isomer

Engineering Contradiction:

Improvemanufacturing simplicityVSAvoidtherapeutic efficacy

Core Design Contradiction:

Ease of manufactureVSProductivity

Solution Approach 1:

The patent introduces an ester group at the chiral center, creating a new chemical structure where only the dextrorotatory isomer is active. This structural parameter change allows for simplified manufacturing using racemic mixture while ensuring high therapeutic efficacy, as the inactive isomer does not form or can be easily separated

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS12606517B2Ibuprofen ester derivative and emulsion preparation thereof

Publication Date: 2026.04.21 NANJING HERON PHARMA SCI & TECH CO LTD

AI summary

The application related to an ibuprofen ester derivative and an emulsion preparation thereof. A carboxyl group of racemic ibuprofen or S-ibuprofen is derivatized so that Compound N9 and a dextrorotatory enantiomer N9(S) thereof are obtained and further prepared into an emulsion preparation, which overcomes the problems of safety and compliance of patients existing in clinical application of existing ibuprofen/dexibuprofen injections and achieves the purposes of reducing vascular irritation, increasing clinical use approaches, and improving the stability of preparations in clinical applications.